The UK and US have concluded a significant bilateral deal that will keep zero levies on British medicine exports being sold in the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This commitment ensures that tariffs on these crucial products will remain at nothing for a duration of the next three years.
This deal follows previous threats to significantly raise duties on branded drug products, with figures mentioned up to one hundred percent.
"This deal between the Britain reinforces the global environment for new treatments and establishes much-needed fairness to American-British medicine commerce," a release noted.
Commercial Significance
Pharmaceuticals are one of the the United Kingdom's most significant exports to the US, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Trade data reveal that in the year leading up to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that period.
"This deal secures work, boosts funding and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double overall public funding on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. In the past, refunds exceeded 20%.
Broader Context
This agreement comes amid a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by assertions that American patients were charged several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
